基于“肠道菌群-胆汁酸互作”探讨代谢相关脂肪性肝病“土壅木郁”的生物学内涵

doi:10.20047/j.issn1673-7210.2022.28.27

Abstract
Figure/Table
References (33)
Related Citation (15)

Download: PDF (701 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Traditional Chinese medicine believes that “earth stagnation and wood constraint” is the main pathogenesis of metabolic associated fatty liver disease. Combined with the pathogenesis theory of traditional Chinese medicine and modern medical research, it is found that the dysregulation of intestinal microbiota is very likely to be an important biological basis of “earth stagnation” (dysfunction of spleen in transportation), and the imbalance of bile acid metabolism may be the microscopic manifestation of “wood constraint” (dysfunction of liver in conveyance and dispersion). The occurrence and development of metabolic associated fatty liver disease caused by the imbalance of “intestinal microbiota-bile acid interaction” from the perspective of western medicine is consistent with the main pathogenesis of “earth stagnation and wood constraint” from the perspective of traditional Chinese medicine. Based on the interaction between intestinal microbiota and bile acids, this paper preliminarily explores the biological connotation of the pathogenesis of “earth stagnation and wood constraint” in metabolic associated fatty liver disease, to provide new ideas for studying the pathogenesis of “earth stagnation and wood constraint” and promoting the prevention and treatment of metabolic associated fatty liver disease with traditional Chinese medicine。

Key words： Metabolic associated fatty liver disease Intestinal microbiota Bile acid Earth stagnation and wood constraint

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YAN Haiyi1 GUO Rui2 GUO Peng1

Cite this article:

YAN Haiyi1 GUO Rui2 GUO Peng1. Discussion on the biological connotation of “earth stagnation and wood constraint” in metabolic associated fatty liver disease based on “intestinal microbiota-bile acid interaction”[J]. 中国医药导报, 2022, 19(28): 124-127,131.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2022.28.27 OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I28/124

[1] Buzzetti E，Pinzani M，Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease（NAFLD）[J]. Metabolism，2016，65（8）：1038-1048.
[2] Evangelakos I，Heeren J，Verkade E，et al. Role of bile acids in inflammatory liver diseases[J]. Semin Immunopathol，2021，43（4）：577-590.
[3] Ji Y，Yin Y，Sun L，et al. The Molecular and Mechanistic Insights Based on Gut-Liver Axis： Nutritional Target for Non-Alcoholic Fatty Liver Disease （NAFLD） Improvement [J]. Int J Mol Sci，2020，21（9）：3066.
[4] 黄元御，孙洽熙.四圣心源[M].北京：中国中医药出版社，2009.
[5] 孙宁宁，叶永安.“土壅木郁”理论及其在肝病临床中的应用[J].世界中医药，2015，10（3）：383-386.
[6] 郑跃杰.肠道菌群功能研究进展[J].中国儿童保健杂志，2017，25（6）：541-543.
[7] Aron-Wisnewsky J，Vigliotti C，Witjes J，et al. Gut microbiota and human NAFLD： disentangling microbial signatures from metabolic disorders [J]. Nat Rev Gastroenterol Hepatol，2020，17（5）：279-297.
[8] Boursier J，Mueller O，Barret M，et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota [J]. Hepatology，2016，63（3）：764-775.
[9] Fei N，Bruneau A，Zhang X，et al. Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease [J]. mBio，2020，11（1）：e03263-19.
[10] 冯文林，伍海涛.从肠道菌群探讨多种疾病从脾论治的机理[J].吉林中医药，2018，38（10）：1124-1127.
[11] 高旅，李侠，史正刚.浅析中医脾运与肠道菌群的相关性[J].中医儿科杂志，2017，13（2）：21-23.
[12] 夏璐，张真真，万贵平.肠道菌群在多囊卵巢综合征中的作用及中医治疗研究进展[J].中国医药科学，2021， 11（24）：77-80.
[13] 韩卓君，吴小平，严明煜，等.中药与肠道菌群相互作用机制探讨[J].世界中医药，2021，16（24）：3591-3595.
[14] 王方园，彭莹莹，杨振弢，等.从脾论治肠道菌群失调型慢性腹泻[J].西部中医药，2020，33（3）：159-162.
[15] 刘又嘉，龙承星，贺璐，等.中医正邪理论的微生态学思考[J].中国微生态学杂志，2017，29（3）：367-369，373.
[16] 郑昊龙，陈丝，宋囡，等.脾虚模型大鼠肠道菌群分布及时效性研究[J].中医杂志，2020，61（14）：1262-1267.
[17] 黄文武，彭颖，王梦月，等.四君子汤及其单味药水煎液对脾虚大鼠肠道菌群的调节作用[J].中国实验方剂学杂志，2019，25（11）：8-15.
[18] de Aguiar Vallim TQ，Tarling EJ，Edwards PA. Pleiotropic roles of bile acids in metabolism [J]. Cell Metab，2013， 17（5）：657-669.
[19] Nimer N，Choucair I，Wang Z，et al. Bile acids profile，histopathological indices and genetic variants for non-alcoholic fatty liver disease progression [J]. Metabolism，2021，116：154457.
[20] Gillard J，Clerbaux LA，Nachit M，et al. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice [J]. JHEP Rep，2021，4（1）：100387.
[21] 严石林，李正华.脉经[M].成都：四川科学技术出版社，2008.
[22] 叶霖.难经正义[M].上海：上海科技出版社，1984.
[23] 周腾腾.胆汁酸谱在非酒精性脂肪性肝病各中医证型的分布情况研究[D].福州：福建中医药大学，2020.
[24] 吴莉.基于Fxr受体柴胡皂苷类成分的利胆作用机制研究[D].太原：山西大学，2018.
[25] 曹秦，黄菲，王婷婷，等.法尼醇X受体基因缺失对雌性小鼠神经行为及神经传递系统的影响[J].中国药理学通报，2015，31（4）：560-564.
[26] Yu J，Zhang H，Chen L，et al. Disease-Associated Gut Microbiota Reduces the Profile of Secondary Bile Acids in Pediatric Nonalcoholic Fatty Liver Disease [J]. Front Cell Infect Microbiol，2021，11：698852.
[27] Selwyn FP，Csanaky IL，Zhang Y，et al. Importance of Large Intestine in Regulating Bile Acids and Glucagon-Like Peptide-1 in Germ-Free Mice [J]. Drug Metab Dispos，2015，43（10）：1544-1556.
[28] Wang K，Liao M，Zhou N，et al. Parabacteroides distasonis Alleviates Obesity and Metabolic Dysfunctions via Production of Succinate and Secondary Bile Acids [J]. Cell Rep， 2019，26（1）：222-235.e5.
[29] Grüner N，Mattner J. Bile Acids and Microbiota： Multifaceted and Versatile Regulators of the Liver-Gut Axis [J]. Int J Mol Sci，2021，22（3）：1397.
[30] Wahlstr?觟m A，Kovatcheva-Datchary P，St?覽hlman M，et al. Induction of farnesoid X receptor signaling in germ-free mice colonized with a human microbiota [J]. J Lipid Res，2017，58（2）：412-419.
[31] Xu M，Cen M，Shen Y，et al. Deoxycholic Acid-Induced Gut Dysbiosis Disrupts Bile Acid Enterohepatic Circulation and Promotes Intestinal Inflammation [J]. Dig Dis Sci，2021，66（2）：568-576.
[32] Zheng X，Huang F，Zhao A，et al. Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice [J]. BMC Biol，2017，15（1）：120.
[33] Urdaneta V，Casadesús J. Interactions between Bacteria and Bile Salts in the Gastrointestinal and Hepatobiliary Tracts [J]. Front Med（Lausanne），2017，4：163.